Ventyx touts early data for potential rival to Bristol Myers psoriasis drug

Ventyx Biosciences on Monday said an experimental immune disease drug it’s been developing succeeded in an early-stage trial and has a chance to prove more potent than a closely watched medicine from Bristol Myers Squibb.